| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | -0.05 | 0.8 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | 0.016 | 0.8 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | 0.032 | 0.8 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |